BIOYGraniteshares YieldBOOST Biotech ETF
Seeks to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index.
By Graniteshares · Launched 2026
Annual Cost
1.07%
#5,693 of 6,175 · expensive
Fund Size
$0.8M
#5,940 of 6,175 · small
Return (1Y)
N/A
Track Record
5 months
#5,401 of 6,175 · young
Performance
Total-return NAV · USDGrowth of $10,000
$10,325+3.3%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
AlternativeRegion
North americaStrategy
Option income
Index tracked
S&P Biotechnology Select Industry Index
Holdings
By weightAsset allocation
Cash
89.7%
Bonds
11.6%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
N/A
Max drawdown
-6.7%Mild
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index.
- Strategy
- Actively manages an ETF that seeks to pay weekly distributions by selling put options on the Underlying Leveraged ETF, which provides exposure to 3 times the daily performance of the Underlying Index. The Fund aims to generate three times the premium from selling options compared to the Underlying Index, allowing for frequent distributions.
- Inception date
- May 4, 2026
- Fund family
- Graniteshares
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BIOY to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-30